THALES
21.9.2022 10:09:38 CEST | Business Wire | Press release
With the past two years resulting in a permanently altered working environment, changes in security were both necessary and notable. Controlling access to applications, data, and systems is an increasingly important aspect of securing any environment and protecting it against both internal and external threats.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220921005005/en/
©Thales
After two years of the pandemic, confidence in addressing certain security risks and threats arising from hybrid and remote work has improved among businesses and organizations around the world. When it comes to secure access to applications, data, and systems, 84% IT professionals this year said they have some degree of confidence in their current user access security systems to enable remote work securely and easily, compared to 56% in 2021. In addition, 60% said this year they were highly confident compared to just 22% last year.
These are among some of the key findings from the 2022 Thales Access Management Index, a global survey of 2,600 IT decision makers, conducted by 451 Research, part of S&P Global Market Intelligence.
Firms Gaining Confidence Addressing Security of Remote Work
Overall, the report findings suggest that firms remain concerned about the security risks of remote work, but those concerns seem to be less severe. At the same time, firms are also growing more confident in the ability of authentication and access management systems to manage those risks. Only 31% of IT professional surveyed reported having “very high” concerns about the security risks and threats of remote work in 2022, down from 39% in 2021, while those who said they were “somewhat concerned” – the most popular response – increased from 43% to 48% in 2022.
Multi-Factor Authentication on the Rise But Not Widespread
While multi-factor authentication (MFA) usage remains most prevalent for remote workers (68%) and privileged users (52%), the report shows that MFA adoption is on the rise for internal and non-IT staff with MFA adoption increasing to 40% compared to 34% in 2021. However, widespread MFA adoption by businesses is still yet to be the norm with just over half (56%) have adopted MFA in their organizations.
Lingering Effects of Pandemic Drive Interest in Access Management, MFA and ZTNA
The survey inquired about direct impacts that the pandemic and remote work had on deployment plans for new access security technologies. Responses revealed a six-percentage-point global increase in plans to deploy stand-alone MFA, up from 31% in 2021. The pandemic also impacted plans to deploy cloud-based access management, selected by 45% of respondents worldwide compared to 41% in 2021. These two increases illustrate respondents’ growing awareness that threats come from all angles, and that proper authentication and management of access and privileges is necessary for an adequate security foundation. Last year, Zero Trust Network Access/Software-Defined Perimeter (ZTNA)/(SDP) was the top choice, selected by 44% of respondents. In 2022, ZTNA was the second choice at 42%.
Francois Lasnier, Vice President of Access Management Solutions at Thales comments: “The past few years have cemented remote work and work-from-anywhere as a permanent part of the security landscape, and they have also introduced new security risks and challenges. However, growing familiarity with remote work has ultimately broadened awareness on an enterprise level of daily business security risks and has strengthened both confidence and ability in security teams and products to handle those risks and threats properly.”
Garrett Bekker, Principal Analyst at 451 Research comments: “Just as the threat landscape has evolved, the tools and methods to handle the landscape have, too. However, even with innovative tools and boosted confidence levels, security plans and approaches still need to adapt to the ever-changing threat environment. A greater shift towards a Zero Trust model would place access management in a central role in corporate security strategies, with a related reliance on MFA as a critical supporting enabler.”
Thales and 451 Research will discuss the findings in more detail during a webinar on 29 September 2022. To join, please visit the registration page.
About the 2022 Thales Access Management Index
As organizations step beyond the urgent actions of the last two years, they’re grappling with securing the more complex environments in which they now operate. The global edition of the 2022 Thales Access Management Index looked at various aspects of those impacts in a wide-ranging survey of security professionals and executive leadership that touched on issues including access management and access security, multi-factor authentication, zero-trust network access, security spending plans, remote work and VPNs, and ransomware. The 2022 Thales Access Management Study is based on data from a survey of nearly 2,800 security professionals and executive leaders in more than 15 countries across the globe. This research was conducted as an observational study and makes no causal claims.
About Thales
Thales (Euronext Paris: HO) is a global leader in advanced technologies, investing in digital and “deep tech” innovations – connectivity, big data, artificial intelligence, cybersecurity and quantum technologies – to build a confident future crucial for the development of our societies. The Group provides its customers – businesses, organizations and governments – in the defense, aeronautics, space, transport, and digital identity and security domains with solutions, services and products that help them fulfil their critical role, consideration for the individual being the driving force behind all decisions.
Thales has 81,000 employees in 68 countries. In 2021, the Group generated sales of €16.2 billion.
PLEASE VISIT
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220921005005/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
